2024-511651-17-00RecruitingPhase 2
NMDSG-14B2
A phase II multicenter single-armed study using subject-specific minimal residual minimal disease markers to adopt treatment after allogeneic stem cell transplantation for subjects with myleodysplastic syndrome - MDS
Source: EU CTIS (euclinicaltrials.eu) · Last updated 27 May 2026
Brief summary (registry, in English)
To prevent clinical events (relapse or non-relapse death) in minimal residual disease (MRD) positive subjects
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 13 Feb 2024
- Start date
- 21 Sept 2021
- Lead sponsor
- Karolinska University Hospital
- Diseases
- Myelodysplastic syndromes
- EU CT number
- 2024-511651-17-00
- EudraCT number
- 2021-003809-22
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 200
- 11 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other illness
- Uncontrolled hypertension, heart, liver, kidney related or other uncontrolled medical or psychiatric disorders
Other
- No traceable genetic aberration identified either in screening next generation sequencing panel or next generation sequencing panel performed at diagnosis
- Mental inability, reluctance or language difficulties that results in difficulty understanding the meaning of study participation
Who the study is looking for
- Signed informed consent
- Age ≥ 18 years
- Subjects eligible for stem cell transplantation
- Subjects having the disease myelodysplastic syndrome (MDS), mixed myelodysplastic/myeloproliferative syndrome or acute myeloid leukemia (AML) with myelodysplasia related dysplasia and 20-29% marrow blasts
- All female subjects of childbearing potential have to have negative pregnancy test within 2 weeks prior to inclusion to the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (11)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Aarhus University Hospital | Aarhus N | Denmark | Recruiting |
| Rigshospitalet | Copenhagen Oe | Denmark | Recruiting |
| HUS-Yhtymae | Helsinki | Finland | Recruiting |
| Helse Bergen HF | Bergen | Norway | Recruiting |
| Oslo University Hospital HF | Oslo | Norway | Recruiting |
| Sahlgrenska University Hospital-Vaestra Goetalandsregionen | Goteborg | Sweden | Recruiting |
| Karolinska University Hospital | Huddinge | Sweden | Recruiting |
| Linkoping University Hospital Region Ostergotland | Linkoping | Sweden | Recruiting |
| Region Skane Skanes Universitetssjukhus | Lund | Sweden | Recruiting |
| Norrlands University Hospital | Umeå | Sweden | Recruiting |
| Uppsala University Hospital | Uppsala | Sweden | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.